Evaluating the tumor immune profile based on a three-gene prognostic risk model in HER2 positive breast cancer

To date, there have not been great breakthroughs in immunotherapy for HER2 positive breast cancer (HPBC). This study aimed to build a risk model that might contribute to predicting prognosis and discriminating the immune landscape in patients with HPBC. We analyzed the tumor immune profile of HPBC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Jianqing, Zhao, Aiyue, Fu, Deqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166798/
https://www.ncbi.nlm.nih.gov/pubmed/35665772
http://dx.doi.org/10.1038/s41598-022-13499-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9166798/
https://www.ncbi.nlm.nih.gov/pubmed/35665772
http://dx.doi.org/10.1038/s41598-022-13499-1

Ejemplares similares